Bioequivalence Study of Generic Fluorouracil 0.5% Cream and 0.5% Carac® and Placebo

Spear Pharmaceuticals

Status and phase: Completed; Phase 3

Conditions: Actinic Keratoses

Treatments: Other: Placebo cream; Drug: Generic 0.5% 5-fluorouracil cream; Drug: Brand Carac

Study type: Interventional

Funder types: Industry

Identifiers

NCT01354717

Spear 0.5%

Details and patient eligibility

About

This is a double-blind, randomized, placebo-controlled, three treatment parallel study in which normal, healthy men and women (age 45-85) with actinic keratosis will be treated on the face once daily for two weeks with 5-Fluorouracil Cream 0.5%, Spear Pharmaceuticals (Generic), Carac® Cream 0.5% (Brand), or Cream Vehicle (Placebo). Actinic keratoses will be counted at the baseline visit and at the visit four weeks following cessation of treatment.

Full description

actinic keratosis

Enrollment: 377 patients

Sex: All

Ages: 45 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Men and women with the presence of actinic keratoses

• Women who have had surgical sterilization or are post-menopausal (absence of menses for at least one year) are eligible. Women of child-bearing potential who are non-pregnant and non-nursing, and willing to avoid pregnancy during the course of the study and during the menstrual cycle following completion of their participation in the study are eligible. (Adequate contraception is defined as regular use of, diaphragm with condoms, IUD with condoms, or systemic contraceptives - if used for at least three months prior to enrollment in the study). A negative pregnancy test is required at entry into the study
• Able to refrain from the use of all other topical medications to the facial area during the treatment period
• Considered reliable and capable of understanding their responsibility and role in the study
• Have provided written informed consent

Exclusion criteria

• History of allergy or hypersensitivity to 5-fluorouracil

  • Known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency
  • Clinical evidence of severe, uncontrolled auto-immune, cardiovascular, gastrointestinal, hematological, hepatic, neurological, pancreatic, pulmonary or renal disease
  • Dermatologic conditions if present on the face such as: atopic dermatitis, basal cell carcinoma, eczema, psoriasis, rosacea, squamous cell carcinoma, or albinism
  • Positive urine pregnancy test in women of child-bearing potential
  • Inability to use adequate birth control measures for women of child-bearing potential, as defined above
  • Serious psychological illness
  • Significant history (within the past year) of alcohol or drug abuse
  • Participation in any clinical research study during the 30 day period preceding study initiation
  • Medical history which, based on the clinical judgment of the investigator, implies an unlikelihood of successful completion of the study
  • Treatment for actinic keratosis or skin cancer in the previous 28 days with the following: topical 5 fluorouracil, cryodestruction (liquid nitrogen spray), curettage (scraping of pre-cancer or skin cancers), surgical removal of skin cancer, photodynamic therapy, surgical excision, topical diclofenac (Solaraze), topical imiquimod (Aldara), topical retinoids if used for actinic keratosis or other treatments for actinic keratoses
  • Application of 1) chemical peel, 2) dermabrasion, 3) laser abrasion, 4) PUVA (psoralen plus ultraviolet A) therapy, or 5) UVB therapy to the face or bald scalp within six months prior to randomization
  • Use of sun lamps or sun tanning beds or booths during the 2 weeks prior to first application until Day 42 visit
  • Any oral (systemic steroids) or topical corticosteroids within 1 month of study entry, except for subjects on chronic low dose corticosteroids less than 5 mg daily for greater than 1 year
  • Use within 1 month of any immunomodulators like interferon, or cytotoxic drugs
  • Prior treatment with systemic 5-fluorouracil or systemic cancer therapy within 6 months of study entry
  • Subjects with lesions suspicious for squamous cell carcinoma

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

377 participants in 3 patient groups, including a placebo group

Brand Carac

Active Comparator group

Description:

Treatment of actinic keratosis with active ingredient

Treatment:

Drug: Brand Carac

Generic 0.5% 5-fluorouracil cream

Active Comparator group

Description:

Treatment of actinic keratosis with active ingredient

Treatment:

Drug: Generic 0.5% 5-fluorouracil cream

Placebo

Placebo Comparator group

Description:

treatment of actinic keratosis with placebo cream

Treatment:

Other: Placebo cream